JP7094879B2 - がんを処置する使用のための複素環式ｐｄｋ１インヒビター - Google Patents

がんを処置する使用のための複素環式ｐｄｋ１インヒビター Download PDF

Info

Publication number
JP7094879B2
JP7094879B2 JP2018520428A JP2018520428A JP7094879B2 JP 7094879 B2 JP7094879 B2 JP 7094879B2 JP 2018520428 A JP2018520428 A JP 2018520428A JP 2018520428 A JP2018520428 A JP 2018520428A JP 7094879 B2 JP7094879 B2 JP 7094879B2
Authority
JP
Japan
Prior art keywords
compound
pdk1
nitrogen
sulfur
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018520428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538244A (ja
JP2018538244A5 (https=
Inventor
スティッグ ケー． ハンセン，
ミンク イー． ビナーツ，
Original Assignee
サネシス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サネシス ファーマシューティカルズ， インコーポレイテッド filed Critical サネシス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2018538244A publication Critical patent/JP2018538244A/ja
Publication of JP2018538244A5 publication Critical patent/JP2018538244A5/ja
Application granted granted Critical
Publication of JP7094879B2 publication Critical patent/JP7094879B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018520428A 2015-10-23 2016-10-21 がんを処置する使用のための複素環式ｐｄｋ１インヒビター Expired - Fee Related JP7094879B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562245606P 2015-10-23 2015-10-23
US62/245,606 2015-10-23
PCT/US2016/058255 WO2017070565A1 (en) 2015-10-23 2016-10-21 Heterocyclic pdk1 inhibitors for use to treat cancer

Publications (3)

Publication Number Publication Date
JP2018538244A JP2018538244A (ja) 2018-12-27
JP2018538244A5 JP2018538244A5 (https=) 2019-11-28
JP7094879B2 true JP7094879B2 (ja) 2022-07-04

Family

ID=57209945

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018520428A Expired - Fee Related JP7094879B2 (ja) 2015-10-23 2016-10-21 がんを処置する使用のための複素環式ｐｄｋ１インヒビター

Country Status (14)

Country Link
US (3) US20190015410A1 (https=)
EP (2) EP3763368A1 (https=)
JP (1) JP7094879B2 (https=)
KR (1) KR20180101329A (https=)
CN (1) CN108697699A (https=)
AU (2) AU2016342352B2 (https=)
BR (1) BR112018008025A2 (https=)
CA (1) CA3002907A1 (https=)
DK (1) DK3364971T3 (https=)
ES (1) ES2820770T3 (https=)
MX (1) MX381727B (https=)
PL (1) PL3364971T3 (https=)
RU (1) RU2018118786A (https=)
WO (1) WO2017070565A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114763326B (zh) * 2021-01-13 2026-01-02 南京宁丹新药技术股份有限公司 一类氨基酸酯衍生物及其用途
EP4323356A1 (en) 2021-04-13 2024-02-21 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
WO2024040242A1 (en) * 2022-08-19 2024-02-22 Viracta Therapeutics, Inc. Combinations of pdk1 inhibitors and kinase inhibitors
WO2024040241A1 (en) 2022-08-19 2024-02-22 Viracta Therapeutics, Inc. Pharmaceutical formulations, processes for preparation, and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506715A (ja) 2009-10-06 2013-02-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｐｄｋ１インヒビターとして有用な複素環式化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
DE102005061655A1 (de) * 2005-12-22 2007-06-28 Merck Patent Gmbh Diazepinone
ES2527363T3 (es) * 2009-12-04 2015-01-22 Nerviano Medical Sciences S.R.L. Derivados de triciclopirazol
WO2019094779A1 (en) * 2017-11-09 2019-05-16 Sunesis Pharmaceuticals, Inc. Pharmaceutical formulations, processes for preparation, and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506715A (ja) 2009-10-06 2013-02-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｐｄｋ１インヒビターとして有用な複素環式化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PNAS, 2014, 111, 52, 18590-18595，2014年

Also Published As

Publication number Publication date
EP3763368A1 (en) 2021-01-13
AU2016342352A1 (en) 2018-05-10
EP3364971B1 (en) 2020-06-17
CN108697699A (zh) 2018-10-23
AU2022203204A1 (en) 2022-06-02
CA3002907A1 (en) 2017-04-27
US20230099829A1 (en) 2023-03-30
JP2018538244A (ja) 2018-12-27
EP3364971A1 (en) 2018-08-29
RU2018118786A (ru) 2019-11-26
KR20180101329A (ko) 2018-09-12
US20240207258A1 (en) 2024-06-27
US20190015410A1 (en) 2019-01-17
DK3364971T3 (da) 2020-09-21
PL3364971T3 (pl) 2021-05-31
AU2016342352B2 (en) 2022-06-02
WO2017070565A1 (en) 2017-04-27
BR112018008025A2 (pt) 2018-10-23
MX2018004977A (es) 2018-07-06
RU2018118786A3 (https=) 2020-02-25
MX381727B (es) 2025-03-13
ES2820770T3 (es) 2021-04-22

Similar Documents

Publication Publication Date Title
US12077507B2 (en) Compositions and methods for treating cancer
US20210030756A1 (en) Chiral diaryl macrocycles and uses thereof
JP2023512040A (ja) 化合物及びその使用
US20230099829A1 (en) Heterocyclic pdk1 inhibitors for use to treat cancer
US9573899B2 (en) USP7 inhibitor compounds and methods of use
CN111053768A (zh) 用于治疗黑素瘤的药物组合
Zhan et al. Design, synthesis, and biological evaluation of novel highly selective polo-like kinase 2 inhibitors based on the tetrahydropteridin chemical scaffold
JP2024533975A (ja) Ｐｉ３ｋアイソフォームアルファを阻害する化合物及びがんを処置するための方法
CA3213359A1 (en) Alk-5 inhibitors and uses thereof
HK40044568A (en) Heterocyclic pdk1 inhibitors for use to treat cancer
HK1259985B (en) Heterocyclic pdk1 inhibitors for use to treat cancer
HK1259985A1 (en) Heterocyclic pdk1 inhibitors for use to treat cancer
HK1262903A1 (en) Heterocyclic pdk1 inhibitors for use to treat cancer
TWI554502B (zh) 受體型激酶調節劑及治療多囊性腎疾病的方法
CN119013271A (zh) Crk样（CrkL）衔接蛋白抑制剂及其制备和使用方法
Chang HI-511 inhibits both BRAF and AURKB to overcome malignant melanoma drug resistance and metastasis
WO2026026768A1 (zh) 杂环取代磺酰胺类化合物、其药物组合物及应用
JP2023513016A (ja) Ｎｅｋ２阻害剤としてのアミノピリミジニルアミノベンゾニトリル誘導体
AU2021359826A1 (en) Dosing regimens for cyclin‑dependent kinase 7 (cdk7) inhibitors
JP2025522438A (ja) フェニルアミド化合物及び使用方法
Soliman et al. dihydroquinazolin-2-yl) thio] acetamide derivatives as anticancer and radiosensitizing agents
HK40026870A (en) A pharmaceutical combination for the treatment of melanoma
WO2013028866A1 (en) Therapeutic compounds and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191018

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220614

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220622

R150 Certificate of patent or registration of utility model

Ref document number: 7094879

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees